Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Liver cancer in 2013

Mutational landscape of HCC—the end of the beginning

Nature Reviews Clinical Oncology volume 11, pages 73–74 (2014)Cite this article

Subjects

Next-generation sequencing analysis and characterization of the microenvironment 'field-effect' that promotes hepatocellular carcinoma (HCC) development has revealed critical players and potential targets for chemoprevention. A biomarker-based drug development strategy is needed to improve future HCC clinical trials and therapies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lonzano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128 (2012).

    Article  Google Scholar 

  2. Cleary, S. P. et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology http://dx.doi.org/10.1002/hep.26540.

  3. Guichard, C. et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44, 694–698 (2012).

    Article  CAS  Google Scholar 

  4. Kan, Z. et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 23, 1422–1433 (2013).

    Article  CAS  Google Scholar 

  5. Chiang, D. Y. et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 68, 6779–6788 (2008).

    Article  CAS  Google Scholar 

  6. Nault, J. C. et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. http://dx.doi.org/10.1038/ncomms3218 (2013).

  7. Johnson, P. J. et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J. Clin. Oncol. 31, 3517–3524 (2013).

    Article  CAS  Google Scholar 

  8. Llovet, J. M. et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J. Clin. Oncol. 31, 3509–3516 (2013).

    Article  CAS  Google Scholar 

  9. Hoshida, Y. et al. Prognostic gene expression signature for patients with hepatitis C-related early stage cirrhosis. Gastroenterology 144, 1024–1030 (2013).

    Article  CAS  Google Scholar 

  10. He, G. et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155, 384–396 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

J. M. Llovet is supported by grants from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK076986-01), European Commission-FP7 Framework (HEPTROMIC, Proposal No: 259,744), the Asociación Española Contra el Cáncer, the Samuel Waxman Cancer Research Foundation and the Spanish National Health Institute (SAF-2010-16055).

Author information

Authors and Affiliations

  1. Division of Transplantation Immunology and Mucosal Biology, Institute of Liver Studies, King's College, Denmark Hill, London, SE5 6FE, UK

    Augusto Villanueva

  2. HCC Translational Research Laboratory, BCLC Group, IDIBAPS, Liver Unit, Hospital Clínic, University of Barcelona and ICREA, Villarroel 170, Barcelona, 08036, Spain

    Josep M. Llovet

Authors
  1. Augusto Villanueva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josep M. Llovet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josep M. Llovet.

Ethics declarations

Competing interests

A. Villanueva is a consultant for Bayer Pharmaceuticals. J.M. Lovet is a consultant for Bayer Pharmaceuticals, Imclone-Lilly, Novartis, BMS, Blueprint, Nanostring and provides research support for Bayer Pharmaceuticals.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Villanueva, A., Llovet, J. Mutational landscape of HCC—the end of the beginning. Nat Rev Clin Oncol 11, 73–74 (2014). https://doi.org/10.1038/nrclinonc.2013.243

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.243

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer